GlassScriptPhysician profile
Kathleen J Meyer
NPI 1477658029
$2,623.23
in general payments reported to CMS, 2019-2025
22 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Neuromusculoskeletal Medicine & Omm provider received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $987 · 2023: $566 · 2024: $518 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $370.71 | 2021-2025 | |
| Abbvie INC. | $353.01 | 2022-2025 | |
| Lilly USA, LLC | $270.06 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $189.99 | 2021-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $181.84 | 2021-2024 | Gattex, Trintellix |
| Otsuka America Pharmaceutical, INC. | $173.23 | 2022-2025 | Rexulti |
| Amgen INC. | $170.06 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $123.08 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $112.45 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $107.60 | 2021-2023 | Farxiga |
| Exact Sciences Corporation | $89.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $87.11 | 2022 | |
| Glaxosmithkline, LLC. | $73.68 | 2022-2024 | Arexvy, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.59 | 2022-2025 | Jardiance |
| Dexcom, INC. | $61.04 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $39.26 | 2021-2022 | |
| Sanofi Pasteur INC. | $39.22 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $36.02 | 2022-2024 | Ajovy |
| Biohaven Pharmaceuticals, INC. | $31.86 | 2021 | |
| Sumitomo Pharma America, INC. | $21.42 | 2025 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $16.67 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.31 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.